☆ 4.6 Review

Past, present, and future of long-term treatment for hepatitis B virus

WORLD JOURNAL OF GASTROENTEROLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Gastroenterology & Hepatology

Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis

Won-Mook Choi et al.

Summary: This study compared the risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients receiving tenofovir disoproxil fumarate (TDF) versus entecavir (ETV) treatment. The results showed that patients receiving TDF had a significantly lower HCC risk, especially those with HBeAg positivity.

JOURNAL OF HEPATOLOGY (2023)

添加到收藏夹

Review Gastroenterology & Hepatology

The scientific basis of combination therapy for chronic hepatitis B functional cure

Seng Gee Lim et al.

Summary: Functional cure of chronic hepatitis B (CHB), achieved through hepatitis B surface antigen (HBsAg) loss after 24 weeks off therapy, is the goal of current treatment. However, the rarity of achieving this cure with current therapy highlights the need for novel approaches. The three categories of treatment include reducing viral replication, reducing antigen load, and immunotherapies. Combination therapy of nucleos(t)ide analogues and immunotherapy shows promise in reducing HBsAg levels and inducing HBsAg loss in some patients, particularly those with low baseline HBsAg levels. Monitoring during therapy using viral and immunological biomarkers is important to predict HBsAg loss and understand its mechanisms.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Liver Complications in Untreated Treatment-Ineligible versus Treated Treatment-Eligible Patients with Hepatitis B

Daniel Q. Huang et al.

Summary: The aim of this study was to determine whether current practice guidelines adequately identify CHB patients who will benefit from antiviral therapy. Through a retrospective cohort study, we found that patients who do not meet treatment criteria have twice the risk of developing cirrhosis and hepatocellular carcinoma compared to patients who are eligible and treated.

DIGESTIVE DISEASES (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma post-liver transplantation: results from a phase I trial

Fan Yang et al.

Summary: This study has demonstrated that multiple infusions of mRNA electroporated HBV-specific TCR T cells were well-tolerated in patients with HBV-positive recurrent HCC post-liver transplant.

HEPATOLOGY INTERNATIONAL (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

A phase 2, open-label, randomized, multiple-dose study evaluating Inarigivir in treatment-naive patients with chronic hepatitis B

Man-Fung Yuen et al.

Summary: Treatment with Inarigivir for HBV infection showed a trend of reducing viral load and antigen levels. A greater reduction in HBsAg was observed in patients pre-treated with Inarigivir after switching to tenofovir.

LIVER INTERNATIONAL (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B

Lung-Yi Mak et al.

Summary: This study investigated the dynamics of serum HBV pre-genomic RNA (pgRNA) and hepatitis B core-related antigen (HBcrAg) in patients receiving nucleos(t)ide analogues (NAs) and their predictability for favourable suppression of serum hepatitis B surface antigen (HBsAg). The results showed that early on-treatment changes of serum HBV pgRNA and HBcrAg at 4 weeks can predict HBsAg seroclearance or <100 IU/mL in NA-treated CHB patients upon long-term follow-up.

CLINICAL AND MOLECULAR HEPATOLOGY (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE)

Milan J. Sonneveld et al.

Summary: In this multicenter study, off-treatment outcomes after NA cessation varied with ethnicity. Lower levels of HBcrAg and HBsAg were associated with favorable outcomes. A risk score comprising both factors can be used for risk stratification.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

On-therapy HBsAg kinetics can predict HBsAg loss after nucleos(t)ide analogues interruption in HBeAg-negative patients. The cup is half full and half empty

Teresa Broquetas et al.

Summary: HBsAg kinetics can predict post-treatment HBsAg loss rate. Half of patients with a significant HBsAg decline can eliminate HBsAg the first year after withdrawal.

DIGESTIVE AND LIVER DISEASE (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study

Lung-Yi Mak et al.

Summary: This study compared the longitudinal changes in estimated glomerular filtration rate (eGFR) in chronic hepatitis B patients treated with entecavir (ETV) versus tenofovir disoproxil fumarate (TDF). The results showed that over 10 years of follow-up, TDF was associated with lower mean eGFR and a higher incidence of renal impairment compared to ETV.

HEPATOLOGY INTERNATIONAL (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels

Milan J. Sonneveld et al.

Summary: The probability of HBsAg loss after NUC cessation varies according to patient ethnicity, HBV genotype and end-of-treatment viral antigen levels. Patients with low HBsAg and HBcrAg levels, particularly non-Asian or infected with HBV genotype C, may be the best candidates for treatment withdrawal.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹

Review Virology

Current Trend in Antiviral Therapy for Chronic Hepatitis B

Rong-Nan Chien et al.

Summary: The goal of treating chronic hepatitis B is to suppress HBV replication to prevent liver damage and complications. Currently, pegylated interferon, entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide are the first-line treatment options. Finite NUC therapy has shown promise in increasing the rate of HBsAg loss in HBeAg-negative patients.

VIRUSES-BASEL (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Switching to or Add-on Peginterferon in Patients on Nucleos(t)ide Analogues for Chronic Hepatitis B: The SWAP RCT

Seng Gee Lim et al.

Summary: For patients with chronic hepatitis B (CHB), switching to or adding peginterferon to nucleoside analogues (NA) is more effective than continuing NA. Adding peginterferon has better safety and similar efficacy compared to switching.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

添加到收藏夹

Review Gastroenterology & Hepatology

RNA interference as a novel treatment strategy for chronic hepatitis B infection

Rex Wan-Hin Hui et al.

Summary: Chronic hepatitis B (CHB) is a major cause of liver-related morbidity and mortality. Current treatment modalities rarely achieve functional cure. RNA interference (RNAi) has been studied as a novel treatment strategy for CHB, targeting viral antigen production and replication. While the evidence on RNAi appears promising, it remains unclear whether it can result in sustained hepatitis B surface antigen (HBsAg) seroclearance.

CLINICAL AND MOLECULAR HEPATOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Impact of expanding hepatitis B treatment guidelines: A modelling and economic impact analysis

Young-Suk Lim et al.

Summary: Simplifying and expanding treatment eligibility for chronic hepatitis B (CHB) in Korea can reduce the incidence of hepatocellular carcinoma (HCC) and save more lives. This measure, combined with high diagnostic rates, is highly cost-effective.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)

添加到收藏夹

Review Gastroenterology & Hepatology

How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?

Grace L. H. Wong et al.

Summary: Functional cure of hepatitis B is defined as sustained undetectable circulating HBsAg and HBV DNA after a finite course of treatment. Current therapies for HBV rarely achieve cure, but novel antiviral and immunomodulatory strategies show promise in increasing the chance of cure through personalized approaches. The development of safe, effective, and affordable curative therapies must be coupled with standardized virologic and immunologic assays to confirm target engagement and to assess response.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

A case of HBV-induced liver failure in the REEF-2 phase II trial: Implications for finite treatment strategies in HBV 'cure'

Kosh Agarwal et al.

Summary: The study describes a severe case of hepatitis B reactivation that occurred shortly after the withdrawal of a nucleoside analogue within a clinical trial. Despite best supportive care and prompt re-introduction of tenofovir, the patient developed subacute liver failure, requiring emergency orthotopic liver transplantation. This case highlights the potential risks of finite therapy and emphasizes the need for improved biomarker-driven strategies and re-evaluation of study protocols.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹

Review Medicine, General & Internal

Capsid Assembly Modulators as Antiviral Agents against HBV: Molecular Mechanisms and Clinical Perspectives

Valerio Taverniti et al.

Summary: Despite the availability of a preventive vaccine, over 250 million people are still affected by chronic hepatitis B virus (HBV) infection, which is a major cause of liver disease and hepatocellular carcinoma. The core protein of HBV plays a crucial role in the virus's life cycle and represents a promising target for the development of new antiviral therapies. Capsid assembly modulators (CAM) have shown potent antiviral activity in cell-based and in vivo models, and several CAMs are currently being developed for clinical use.

JOURNAL OF CLINICAL MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection

Man-Fung Yuen et al.

Summary: Bepirovirsen treatment for 24 weeks at a dose of 300 mg per week resulted in sustained loss of hepatitis B surface antigen (HBsAg) and HBV DNA in 9%-10% of patients with chronic HBV infection. Larger and longer trials are needed to assess the efficacy and safety of bepirovirsen.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy

Man-Fung Yuen et al.

Summary: This study evaluated the safety and efficacy of GSK3389404, a drug targeting chronic HBV infection. The results showed that GSK3389404 can reduce the production of HBV viral proteins, although no optimal dosing regimen was identified.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹

Review Immunology

Novel therapeutic strategies for chronic hepatitis B

Sandra Phillips et al.

Summary: The last few years have seen significant progress in the development of drugs for hepatitis B, including direct-acting antivirals and host-targeted therapies. Therapeutic vaccines and drugs directly targeting the key factors of hepatitis B persistence hold promise. The field of hepatitis B research also includes other potential treatments.

VIRULENCE (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019

Brittney S. Sheena et al.

Summary: This study estimated the global, regional, and national prevalence of HBV, as well as mortality and DALYs due to HBV in 2019. It found a decline in HBV infection rates in different age groups, but an increase in HBV-related deaths. Many countries have reached the target for HBV infection rates in children, but targets for reducing deaths and cases have not been met, and progress needs to be accelerated to achieve the 2030 goals.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)

添加到收藏夹

Review Gastroenterology & Hepatology

Should Treatment Indications for Chronic Hepatitis B Be Expanded?

Wen-Juei Jeng et al.

Summary: Current treatment for chronic hepatitis B virus (HBV) does not eradicate the virus, requiring long-term maintenance for most patients. Expanding treatment to certain patient populations, such as immune tolerant patients and those with evidence of liver disease, is supported by available evidence. However, data supporting treatment expansion for confirmed inactive carriers and other immune tolerant patients is lacking. New therapies that can achieve HBsAg loss in a high percentage of patients after a finite course of treatment may allow for more liberal HBV treatment indications in the future.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B

Maria Pfefferkorn et al.

Summary: This study found that the decline in MHBs levels occurred earlier than HBsAg loss before treatment, and the proportion of MHBs was the best predictor of HBsAg loss before NA treatment. LHBs and MHBs show promise as novel biomarkers for predicting the cure of chronic HBV infection.

JOURNAL OF HEPATOLOGY (2021)

添加到收藏夹

Article Immunology

Improving the Prediction of Relapse After Nucleos(t)ide Analogue Discontinuation in Patients With Chronic Hepatitis B

Do Seon Song et al.

Summary: This study identified end-of-therapy HBsAg levels, consolidation duration, and cirrhosis as key determinants of off-therapy relapse. Extended consolidation therapy for >= 2 years, in combination with low HBsAg levels, is recommended for HBeAg-positive patients, while the risk of relapse in HBeAg-negative patients is mainly associated with HBsAg levels.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients

Mireia Garcia-Lopez et al.

Summary: Factors contributing to successful outcome upon nucleos(t)ide analogue treatment withdrawal in HBeAg-negative chronic hepatitis B patients include low HBsAg levels, decreased cccDNA transcription, and the presence of functional HBV-specific T cells. Moreover, a high frequency of functional HBV-specific CD8+ T cells at baseline is associated with sustained viral control off treatment. This study highlights the importance of virological and immunological factors in guiding individualized therapy for chronic hepatitis B patients.

JOURNAL OF HEPATOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial

Fanping Meng et al.

Summary: The study demonstrates that the adoptive transfer of HBV-specific TCR redirected T cells into advanced HBV-HCC patients is generally safe and well-tolerated, with some clinical efficacy observed. These findings support the continued development and eventual application of this treatment strategy in patients with advanced HBV-related HCC.

HEPATOLOGY INTERNATIONAL (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Safety, Pharmacokinetics, and Pharmacodynamics of the Oral TLR8 Agonist Selgantolimod in Chronic Hepatitis B

Edward J. Gane et al.

Summary: Selgantolimod was found to be safe and well-tolerated in patients with chronic hepatitis B (CHB), inducing cytokine responses and antiviral immunity. Although some patients experienced adverse events and laboratory abnormalities, they were mild or moderate in severity. Further studies with longer treatment durations are needed to assess efficacy.

HEPATOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients

Lung-Yi Mak et al.

Summary: The study found that in CHB patients, those treated with entecavir and tenofovir showed significantly lower serum HBcrAg levels at 48 weeks and 96 weeks after treatment, with a slightly higher reduction in the tenofovir group. However, there was no significant difference in the reduction of HBcrAg levels between patients treated with tenofovir and tenofovir alafenamide.

BMC GASTROENTEROLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

The times they are a-changing - A refined proposal for finite HBV nucleos(t)ide analogue therapy

Thomas Berg et al.

Summary: The appropriateness of considering HBsAg loss before discontinuation of nucleos(t)ide analogues (NA) treatment in the HBeAg-negative phase remains highly controversial. Although some HBeAg-negative patients can be cured by stopping NA treatment, concerns about discontinuation-associated relapse and uncertainty in predicting off-therapy response have led to low implementation of this concept in the clinic.

JOURNAL OF HEPATOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation

Takako Inoue et al.

Summary: A fully automated, novel high-sensitivity hepatitis B core-related antigen assay (iTACT-HBcrAg) has been developed for monitoring chronic hepatitis B (CHB) and for the early detection of HBV reactivation. The clinical performance of iTACT-HBcrAg was compared with other HBV markers, showing satisfactory analytical performance and potential as a general marker of disease progression and treatment response.

JOURNAL OF HEPATOLOGY (2021)

添加到收藏夹

Article Immunology

Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B

Yao-Chun Hsu et al.

Summary: In patients with chronic hepatitis B treated with ETV or TDF, the occurrence of HBsAg seroclearance is rare and is associated with low-level viremia, elevated alanine aminotransferase levels, bilirubin levels, and fatty liver.

JOURNAL OF INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Cell Biology

Clearance of pegylated interferon by Kupffer cells limits NK cell activation and therapy response of patients with HBV infection

Akira Nishio et al.

Summary: The study found that early NK cell activation in patients with chronic HBV infection is associated with better treatment outcomes, while delayed increases in PEG-IFN-alpha concentration may lead to impaired immune responses. These results reveal the important role of PEG-IFN-alpha in treatment, with its immunomodulatory functions being affected by pharmacokinetics.

SCIENCE TRANSLATIONAL MEDICINE (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Comparison of Long-Term Clinical Outcomes Between Spontaneous and Therapy-Induced HBsAg Seroclearance

Jonggi Choi et al.

Summary: The study found that the risks of HCC and clinical events were not significantly different between spontaneous and NUC-induced HBsAg seroclearance. However, even after HBsAg seroclearance, the annual risk of HCC exceeds the recommended cutoff for HCC surveillance, suggesting continued monitoring is necessary.

HEPATOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

HBV RNA Profiles in Patients With Chronic Hepatitis B Under Different Disease Phases and Antiviral Therapy

Lung-Yi Mak et al.

Summary: This study explored the profile of HBV RNA in patients with chronic hepatitis B and its correlation with other viral markers. The results showed distinct profiles of HBV RNA in patients at different disease phases and its strong correlation with HBcrAg. NA treatment could effectively reduce serum HBV RNA levels in treatment-naive patients. Monitoring of viral activities through serum HBV RNA is still possible in patients with undetectable HBV DNA.

HEPATOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study)

Grishma Hirode et al.

GASTROENTEROLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg-Negative Chronic Hepatitis B

Florian van Boemmel et al.

Summary: Discontinuation of nucleos(t)ide analogues is an effective strategy for achieving control over HBeAg-negative HBV infections, with up to 20% long-term HBsAg loss rates reported in prospective trials. Low HBsAg levels at cessation of treatment predict a positive long-term response to NA discontinuation.

HEPATOLOGY COMMUNICATIONS (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Comparative biomarkers for HBsAg loss with antiviral therapy shows dominant influence of quantitative HBsAg (qHBsAg)

Seng Gee Lim et al.

Summary: This study evaluated the role of qHBsAg, HBV RNA, and qHBcrAg in predicting HBsAg loss in CHB patients, finding that on-treatment biomarker predictors were more effective than baseline ones. The best predictor of HBsAg loss at 72 weeks was a qHBsAg level <70 IU/mL at week 8.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China

Terry Cheuk-Fung Yip et al.

GASTROENTEROLOGY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naive patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis

Sung Won Lee et al.

GUT (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Pregenomic HBV RNA and Hepatitis B Core-Related Antigen Predict Outcomes in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy

Ivana Carey et al.

HEPATOLOGY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Comparison of HBsAg changes between HBeAg-negative patients who discontinued or maintained entecavir therapy

Chien-Hung Chen et al.

HEPATOLOGY INTERNATIONAL (2020)

添加到收藏夹

Letter Gastroenterology & Hepatology

The HBeAg-Negative Gray Zone Phase: A Frequent Condition With Different Outcomes in Western and Asian Patients?

Martin Bonacci et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Knockdown of Virus Antigen Expression Increases Therapeutic Vaccine Efficacy in High-titer HBV Carrier Mice

Thomas Michler et al.

GASTROENTEROLOGY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naive to Nucleos(t)ide Therapy

Michel Bazinet et al.

GASTROENTEROLOGY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Re-treatment for severe hepatitis flare in HBeAg-negative chronic hepatitis B: An appraisal with combined HBsAg/ALT kinetics

Rong-Nan Chien et al.

JOURNAL OF VIRAL HEPATITIS (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Association Between Seroclearance of Hepatitis B Surface Antigen and Long-term Clinical Outcomes of Patients With Chronic HBV Infection: Systematic Review and Meta-analysis

Ryan T. Anderson et al.

Clinical Gastroenterology and Hepatology (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

Characterization of the antiviral effects of REP 2139 on the HBV lifecycle in vitro

Richard Boulon et al.

ANTIVIRAL RESEARCH (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B

George Papatheodoridis et al.

JOURNAL OF HEPATOLOGY (2020)

添加到收藏夹

Review Virology

Advances with RNAi-Based Therapy for Hepatitis B Virus Infection

Fiona van den Berg et al.

VIRUSES-BASEL (2020)

添加到收藏夹

Review Medicine, General & Internal

New Approaches to the Treatment of Chronic Hepatitis B

Alexandra Alexopoulou et al.

JOURNAL OF CLINICAL MEDICINE (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Hepatitis B surface antigen and hepatitis B core-related antigen kinetics after adding pegylated-interferon to nucleos(t)ids analogues in hepatitis B e antigen-negative patients

Teresa Broquetas et al.

WORLD JOURNAL OF HEPATOLOGY (2020)

添加到收藏夹

Review Gastroenterology & Hepatology

Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis

Jiaye Liu et al.

HEPATOLOGY INTERNATIONAL (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection

Patrick Marcellin et al.

LIVER INTERNATIONAL (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis

Thomas Yau et al.

JOURNAL OF HEPATOLOGY (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis

Ken Liu et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)

添加到收藏夹

Review Gastroenterology & Hepatology

Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift

Yun-Fan Liaw

HEPATOLOGY INTERNATIONAL (2019)

添加到收藏夹

Review Gastroenterology & Hepatology

Restoring, releasing or replacing adaptive immunity in chronic hepatitis B

Mala K. Maini et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)

添加到收藏夹

Article Oncology

Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B A Korean Nationwide Cohort Study

Jonggi Choi et al.

JAMA ONCOLOGY (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir

Ming-Te Kuo et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)

添加到收藏夹

Letter Gastroenterology & Hepatology

Progression of Untreated Minimally Active Chronic HBV Infection Compared to Inactive Infection

Hye Won Lee et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)

添加到收藏夹

Review Gastroenterology & Hepatology

The Role of Hepatitis B Surface Antigen in Nucleos(t)ide Analogues Cessation Among Asian Patients With Chronic Hepatitis B: A Systematic Review

Jiaye Liu et al.

HEPATOLOGY (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Declining in liver stiffness cannot indicate fibrosis regression in patients with chronic hepatitis B: A 78-week prospective study

Xiao-Qin Dong et al.

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients

Barbara Testoni et al.

JOURNAL OF HEPATOLOGY (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir

Yuanyuan Kong et al.

JOURNAL OF VIRAL HEPATITIS (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide

Tse-Ling Fong et al.

JOURNAL OF VIRAL HEPATITIS (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

HBeAg seroconversion is associated with a more effective PD-L1 blockade during chronic hepatitis B infection

Sara Ferrando-Martinez et al.

JHEP REPORTS (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B

Gi-Ae Kim et al.

GUT (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers

Maria Pfefferkorn et al.

GUT (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Anti-viral therapy can be delayed or avoided in a significant proportion of HBeAg-negative Caucasian patients in the Grey Zone

M. Bonacci et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)

添加到收藏夹

Review Gastroenterology & Hepatology

Systematic review with meta-analysis: Change in liver stiffness during anti-viral therapy in patients with hepatitis B

Antonio Facciorusso et al.

DIGESTIVE AND LIVER DISEASE (2018)

添加到收藏夹

Review Pharmacology & Pharmacy

Recent advances in the discovery and development of TLR ligands as novel therapeutics for chronic HBV and HIV infections

Keye Du et al.

EXPERT OPINION ON DRUG DISCOVERY (2018)

添加到收藏夹

Letter Gastroenterology & Hepatology

HBsAg Kinetics in Retreatment Decision for Off-Therapy Hepatitis B Flare in HBeAg-Negative Patients

Yun-Fan Liaw et al.

GASTROENTEROLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues

Carolina Boni et al.

GASTROENTEROLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Hepatitis B Virus Serum DNA and RNA Levels in Nucleos(t)ide Analog-Treated or Untreated Patients During Chronic and Acute Infection

Emily K. Butler et al.

HEPATOLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B

Wen-Juei Jeng et al.

HEPATOLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

Norah A. Terrault et al.

HEPATOLOGY (2018)

添加到收藏夹

Article Medicine, Research & Experimental

Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation

Laura Rivino et al.

JOURNAL OF CLINICAL INVESTIGATION (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B

Harry L. A. Janssen et al.

JOURNAL OF HEPATOLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B

Franziska Rinker et al.

JOURNAL OF HEPATOLOGY (2018)

添加到收藏夹

Article Immunology

Divergent preS Sequences in Virion-Associated Hepatitis B Virus Genomes and Subviral HBV Surface Antigen Particles From HBV e Antigen-Negative Patients

Kai-Henrik Peiffer et al.

JOURNAL OF INFECTIOUS DISEASES (2018)

添加到收藏夹

Review Gastroenterology & Hepatology

Systematic review of risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance

X. -J. Kuang et al.

JOURNAL OF VIRAL HEPATITIS (2018)

添加到收藏夹

Article Medicine, General & Internal

Hepatitis B virus infection

Man-Fung Yuen et al.

NATURE REVIEWS DISEASE PRIMERS (2018)

添加到收藏夹

Article Infectious Diseases

Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients

C. -H. Chen et al.

CLINICAL MICROBIOLOGY AND INFECTION (2018)

添加到收藏夹

Review Immunology

The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: A systematic review and Meta-analysis

Ying Han et al.

INTERNATIONAL IMMUNOPHARMACOLOGY (2017)

添加到收藏夹

Article Gastroenterology & Hepatology

Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B

Fanny Lebosse et al.

JOURNAL OF HEPATOLOGY (2017)

添加到收藏夹

Letter Gastroenterology & Hepatology

Serum HBV pgRNA as a clinical marker for cccDNA activity

Katja Giersch et al.

JOURNAL OF HEPATOLOGY (2017)

添加到收藏夹

Article Gastroenterology & Hepatology

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

JOURNAL OF HEPATOLOGY (2017)

添加到收藏夹

Article Gastroenterology & Hepatology

Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study

Thomas Berg et al.

JOURNAL OF HEPATOLOGY (2017)

添加到收藏夹

Article Immunology

Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study

Young Chang et al.

JOURNAL OF INFECTIOUS DISEASES (2017)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Anthony B. El-Khoueiry et al.

LANCET (2017)

添加到收藏夹

Article Gastroenterology & Hepatology

Long-term outcome of inactive and active, low viraemic HBeAg-negative-hepatitis B virus infection: Benign course towards HBsAg clearance

Filippo Oliveri et al.

LIVER INTERNATIONAL (2017)

添加到收藏夹

Article Gastroenterology & Hepatology

Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs)

Glenda Grossi et al.

LIVER INTERNATIONAL (2017)

添加到收藏夹

Article Cell Biology

RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg

Christine I. Wooddell et al.

SCIENCE TRANSLATIONAL MEDICINE (2017)

添加到收藏夹

Review Virology

Complete and Incomplete Hepatitis B Virus Particles: Formation, Function, and Application

Jianming Hu et al.

VIRUSES-BASEL (2017)

添加到收藏夹

Article Gastroenterology & Hepatology

Seven-Year Treatment Outcome of Entecavir in a Real-World Cohort: Effects on Clinical Parameters, HBsAg and HBcrAg Levels

Yuk-Fai Lam et al.

CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Quantification of HBsAg to predict low levels and seroclearance in HBeAg-negative patients receiving nucleos(t)ide analogues

Teresa Broquetas et al.

PLOS ONE (2017)

添加到收藏夹

Article Gastroenterology & Hepatology

Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial

Marc Bourliere et al.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)

添加到收藏夹

Article Gastroenterology & Hepatology

Entecavir safety and effectiveness in a national cohort of treatment-naive chronic hepatitis B patients in the US - the ENUMERATE study

J. Ahn et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)

添加到收藏夹

Article Gastroenterology & Hepatology

Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update

S. K. Sarin et al.

HEPATOLOGY INTERNATIONAL (2016)

添加到收藏夹

Article Immunology

Bone mineral density decline according to renal tubular dysfunction and phosphaturia in tenofovir-exposed HIV-infected patients

Jose L. Casado et al.

AIDS (2016)

添加到收藏夹

Article Gastroenterology & Hepatology

Combination of Tenofovir Disoproxil Fumarate and Peginterferon alpha-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B

Patrick Marcellin et al.

GASTROENTEROLOGY (2016)

添加到收藏夹

Review Gastroenterology & Hepatology

Discontinuation of oral antivirals in chronic hepatitis B: A systematic review

George Papatheodoridis et al.

HEPATOLOGY (2016)

添加到收藏夹

Review Gastroenterology & Hepatology

Hepatitis B virus receptors and molecular drug targets

Eloi R. Verrier et al.

HEPATOLOGY INTERNATIONAL (2016)

添加到收藏夹

Article Gastroenterology & Hepatology

Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B

Anna S. Lok et al.

JOURNAL OF HEPATOLOGY (2016)

添加到收藏夹

Article Gastroenterology & Hepatology

Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study

Pavel Bogomolov et al.

JOURNAL OF HEPATOLOGY (2016)

添加到收藏夹

Article Gastroenterology & Hepatology

Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound

Jie Wang et al.

JOURNAL OF HEPATOLOGY (2016)

添加到收藏夹

Review Gastroenterology & Hepatology

Mechanisms of HBV-induced hepatocellular carcinoma

Massimo Levrero et al.

JOURNAL OF HEPATOLOGY (2016)

添加到收藏夹

Review Gastroenterology & Hepatology

Overview of hepatitis B viral replication and genetic variability

Shuping Tong et al.

JOURNAL OF HEPATOLOGY (2016)

添加到收藏夹

Article Gastroenterology & Hepatology

PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy

George Papatheodoridis et al.

JOURNAL OF HEPATOLOGY (2016)

添加到收藏夹

Article Immunology

Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B

Christoph Hoener zu Siederdissen et al.

JOURNAL OF INFECTIOUS DISEASES (2016)

添加到收藏夹

Article Gastroenterology & Hepatology

Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients

Tung-Hung Su et al.

LIVER INTERNATIONAL (2016)

添加到收藏夹

Review Microbiology

Viral evasion of intracellular DNA and RNA sensing

Ying Kai Chan et al.

NATURE REVIEWS MICROBIOLOGY (2016)

添加到收藏夹

Article Gastroenterology & Hepatology

Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial

Henry L. Y. Chan et al.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2016)

添加到收藏夹

Article Gastroenterology & Hepatology

Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial

Maria Buti et al.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2016)

添加到收藏夹

Article Gastroenterology & Hepatology

Quantification of HBsAg in nucleos(t)ide-naive patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study

Fabien Zoulim et al.

JOURNAL OF HEPATOLOGY (2015)

添加到收藏夹

Review Virology

Molecular biology of hepatitis B virus infection

Christoph Seeger et al.

VIROLOGY (2015)

添加到收藏夹

Review Chemistry, Medicinal

Targeting Viral Entry for Treatment of Hepatitis B and C Virus Infections

Che C. Colpitts et al.

ACS INFECTIOUS DISEASES (2015)

添加到收藏夹

Article Gastroenterology & Hepatology

Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study

Wai-Kay Seto et al.

GUT (2015)

添加到收藏夹

Article Gastroenterology & Hepatology

Serum Hepatitis B Virus RNA Levels as an Early Predictor of Hepatitis B Envelope Antigen Seroconversion During Treatment With Polymerase Inhibitors

Florian van Boemmel et al.

HEPATOLOGY (2015)

添加到收藏夹

Article Pharmacology & Pharmacy

Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon

Lucio Boglione et al.

ANTIVIRAL RESEARCH (2014)

添加到收藏夹

Article Gastroenterology & Hepatology

The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment

Chien-Hung Chen et al.

JOURNAL OF HEPATOLOGY (2014)

添加到收藏夹

Article Multidisciplinary Sciences

Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA

Julie Lucifora et al.

SCIENCE (2014)

添加到收藏夹

Editorial Material Gastroenterology & Hepatology

Kinetics of Intrahepatic Covalently Closed Circular DNA and Serum Hepatitis B Surface Antigen During Antiviral Therapy for Chronic Hepatitis B: Lessons From Experimental and Clinical Studies

Fabien Zoulim et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2013)

添加到收藏夹

Article Gastroenterology & Hepatology

Reduction of Hepatitis B Surface Antigen and Covalently Closed Circular DNA by Nucleos(t)ide Analogues of Different Potency

Danny Ka-Ho Wong et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2013)

添加到收藏夹

Editorial Material Gastroenterology & Hepatology

BASIC AND TRANSLATIONAL-LIVER

Robert E. Lanford et al.

GASTROENTEROLOGY (2013)

添加到收藏夹

Article Gastroenterology & Hepatology

IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B

Pietro Lampertico et al.

HEPATOLOGY (2013)

添加到收藏夹

Article Gastroenterology & Hepatology

Entecavir Treatment Reduces Hepatic Events and Deaths in Chronic Hepatitis B Patients With Liver Cirrhosis

Grace Lai-Hung Wong et al.

HEPATOLOGY (2013)

添加到收藏夹

Article Gastroenterology & Hepatology

Reduction of Hepatitis B Surface Antigen Levels and Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B Patients Receiving 10 Years of Nucleoside Analogue Therapy

Wai-Kay Seto et al.

HEPATOLOGY (2013)

添加到收藏夹

Article Gastroenterology & Hepatology

Response-Guided Peginterferon Therapy in Hepatitis B e Antigen-Positive Chronic Hepatitis B Using Serum Hepatitis B Surface Antigen Levels

Milan J. Sonneveld et al.

HEPATOLOGY (2013)

添加到收藏夹

Article Gastroenterology & Hepatology

Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients

Patrick Marcellin et al.

HEPATOLOGY INTERNATIONAL (2013)

添加到收藏夹

Article Gastroenterology & Hepatology

Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: Finite treatment duration unlikely

Stephane Chevaliez et al.

JOURNAL OF HEPATOLOGY (2013)

添加到收藏夹

Article Medicine, General & Internal

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

Patrick Marcellin et al.

LANCET (2013)

添加到收藏夹

Article Gastroenterology & Hepatology

Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D

Lucio Boglione et al.

LIVER INTERNATIONAL (2013)

添加到收藏夹

Review Virology

Medical Virology of Hepatitis B: how it began and where we are now

Wolfram H. Gerlich

VIROLOGY JOURNAL (2013)

添加到收藏夹

Article Gastroenterology & Hepatology

Sustained Responses and Loss of HBsAg in HBeAg-Negative Patients With Chronic Hepatitis B Who Stop Long-Term Treatment With Adefovir

Stephanos J. Hadziyannis et al.

GASTROENTEROLOGY (2012)

添加到收藏夹

Article Gastroenterology & Hepatology

Restored Function of HBV-Specific T Cells After Long-term Effective Therapy With Nucleos(t)ide Analogues

Carolina Boni et al.

GASTROENTEROLOGY (2012)

添加到收藏夹

Review Gastroenterology & Hepatology

Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs

Joerg Petersen et al.

EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2012)

添加到收藏夹

Article Gastroenterology & Hepatology

Entecavir Treatment for up to 5 Years in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

Ting-Tsung Chang et al.

HEPATOLOGY (2010)

添加到收藏夹

Article Gastroenterology & Hepatology

Long-Term Entecavir Therapy Results in the Reversal of Fibrosis/Cirrhosis and Continued Histological Improvement in Patients with Chronic Hepatitis B

Ting-Tsung Chang et al.

HEPATOLOGY (2010)

添加到收藏夹

Review Gastroenterology & Hepatology

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

Yun-Fan Liaw et al.

HEPATOLOGY INTERNATIONAL (2008)

添加到收藏夹

Article Medicine, General & Internal

Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B

GKK Lau et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)

添加到收藏夹

Article Gastroenterology & Hepatology

Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection

F van Bömmel et al.

HEPATOLOGY (2004)

添加到收藏夹

Article Multidisciplinary Sciences

Nuclear import of hepatitis B virus capsids and release of the viral genome

B Rabe et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)

添加到收藏夹

Article Gastroenterology & Hepatology

Interferon α treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B

EK Manesis et al.

GASTROENTEROLOGY (2001)

添加到收藏夹

Article Multidisciplinary Sciences

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

SM Elbashir et al.

NATURE (2001)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.